Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Aarsland, D. Articles by Tandberg, E. Search for Related Content PubMed Citation Articles by Aarsland, D. Articles by Tandberg, E. Schizophrenia Spectrum Disorders

Olanzapine for Psychosis in Patients With Parkinson's Disease With and Without Dementia

Received October 9, 1998; revised December 7, 1998; accepted January 14, 1999. From the Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital, and the Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway. Address correspondence to Dr. Aarsland, Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital, P.O. Box 1163 Hillevåg, 4004 Stavanger, Norway. e-mail: aarsland{at}netpower.no

ABSTRACT

Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine. Eight subjects had dementia. Six subjects (29%) discontinued treatment prematurely because of drowsiness. Delusions and hallucinations improved significantly, and 80% were rated as much or very much improved. There was no worsening of parkinsonism or cognition.

Key Words: Parkinson's Disease • Psychosis • Olanzapine

This article has been cited by other articles:

				U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 414 - 419. [Abstract] [Full Text] [PDF]

				N. Turjanski and G. G. Lloyd Psychiatric side-effects of medications: recent developments Advan. Psychiatr. Treat., January 1, 2005; 11(1): 58 - 70. [Abstract] [Full Text] [PDF]

				D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]

				M. S. Ismail and I. H. Richard A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease? J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 8 - 18. [Abstract] [Full Text] [PDF]

				R. Moretti, P. Torre, R. M. Antonello, G. Cazzato, S. Griggio, and A. Bava Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients American Journal of Alzheimer's Disease and Other Dementias, July 1, 2003; 18(4): 205 - 214. [Abstract] [PDF]

				L. Marsh, C. Lyketsos, and S. G. Reich Olanzapine for the Treatment of Psychosis in Patients With Parkinson's Disease and Dementia Psychosomatics, December 1, 2001; 42(6): 477 - 481. [Abstract] [Full Text] [PDF]

				I. H. Richard and J. Nutt Worsening of motor function in Parkinson's disease: A ""typical"" response to ""atypical"" antipsychotic medications Neurology, September 26, 2000; 55(6): 748 - 749. [Full Text] [PDF]

				C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients Neurology, September 26, 2000; 55(6): 789 - 794. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us